NURS 6521N Advanced Pharmacology Midterm Exam
QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines |
Graded A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Question 1
A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed a highly
protein-bound medication. The nurse practitioner understands that the free
(active) drug concentration will be:
A. Decreased due to increased protein binding capacity
B. Increased due to reduced albumin available for protein binding
C. Unchanged because protein binding does not affect drug activity
D. Decreased because the liver metabolizes the drug more rapidly
Answer: B
Rationale: Hypoalbuminemia (low serum albumin) reduces the number of protein-
binding sites available for highly protein-bound drugs (e.g., phenytoin, warfarin,
valproic acid). This results in a HIGHER concentration of FREE (unbound) drug,
which is the pharmacologically active form. This increases the risk of drug toxicity
even at "normal" total drug levels. Cirrhosis further complicates this by reducing
hepatic metabolism and drug clearance.
Question 2
Which of the following routes of administration bypasses first-pass hepatic
metabolism?
A. Oral
B. Sublingual
,C. Enteral via NG tube
D. Oral extended-release formulation
Answer: B
Rationale: First-pass metabolism occurs when orally administered drugs are
absorbed from the GI tract and transported via the portal vein to the liver, where
they are partially metabolized BEFORE reaching systemic circulation. Routes that
BYPASS first-pass metabolism include sublingual, buccal, intravenous,
intramuscular, subcutaneous, transdermal, and inhalation. Sublingual
administration drains directly into the superior vena cava via the sublingual vein,
completely bypassing the liver.
Question 3
A medication has a half-life of 8 hours. How long will it take to reach
approximately 94% steady-state concentration with consistent dosing?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32-40 hours (4-5 half-lives)
Answer: D
Rationale: Steady-state concentration is reached after approximately 4-5 half-lives.
With a half-life of 8 hours, 4-5 half-lives equals 32-40 hours. At this point,
approximately 94% of steady-state concentration is achieved. This principle is
essential for understanding when therapeutic drug levels will be attained after
initiating therapy.
Question 4
The NP prescribes a medication that is a substrate of CYP3A4. The patient is also
taking Clarithromycin (a strong CYP3A4 inhibitor). What is the expected effect on
the substrate medication?
, A. Decreased serum concentration and reduced therapeutic effect
B. Increased serum concentration and increased risk of toxicity
C. No change in serum concentration
D. Increased rate of metabolism
Answer: B
Rationale: CYP3A4 INHIBITORS (Clarithromycin, Erythromycin, Ketoconazole,
Itraconazole, Grapefruit juice, Ritonavir) DECREASE the metabolism of CYP3A4
substrates, leading to INCREASED serum concentrations and risk of TOXICITY.
Classic interactions: Clarithromycin + Simvastatin → increased rhabdomyolysis
risk. The NP should consider using an alternative antibiotic (e.g., Azithromycin,
which does not inhibit CYP3A4 significantly).
Question 5
A drug with a narrow therapeutic index (NTI) requires:
A. Less frequent monitoring
B. Close monitoring of serum drug levels to avoid toxicity or therapeutic failure
C. Higher than standard dosing
D. No special considerations
Answer: B
Rationale: Narrow Therapeutic Index (NTI) drugs have a small margin between the
minimum effective concentration and the minimum toxic concentration. Small
changes in dose, absorption, metabolism, or excretion can result in subtherapeutic
or toxic levels. Examples: Warfarin, Digoxin, Phenytoin, Theophylline, Lithium,
Aminoglycosides. NTI drugs require therapeutic drug monitoring.
Question 6
Which of the following best describes a competitive antagonist?
A. Binds to the same receptor site as the agonist and can be overcome by
increasing the agonist concentration
QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines |
Graded A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Question 1
A 68-year-old patient with cirrhosis and hypoalbuminemia is prescribed a highly
protein-bound medication. The nurse practitioner understands that the free
(active) drug concentration will be:
A. Decreased due to increased protein binding capacity
B. Increased due to reduced albumin available for protein binding
C. Unchanged because protein binding does not affect drug activity
D. Decreased because the liver metabolizes the drug more rapidly
Answer: B
Rationale: Hypoalbuminemia (low serum albumin) reduces the number of protein-
binding sites available for highly protein-bound drugs (e.g., phenytoin, warfarin,
valproic acid). This results in a HIGHER concentration of FREE (unbound) drug,
which is the pharmacologically active form. This increases the risk of drug toxicity
even at "normal" total drug levels. Cirrhosis further complicates this by reducing
hepatic metabolism and drug clearance.
Question 2
Which of the following routes of administration bypasses first-pass hepatic
metabolism?
A. Oral
B. Sublingual
,C. Enteral via NG tube
D. Oral extended-release formulation
Answer: B
Rationale: First-pass metabolism occurs when orally administered drugs are
absorbed from the GI tract and transported via the portal vein to the liver, where
they are partially metabolized BEFORE reaching systemic circulation. Routes that
BYPASS first-pass metabolism include sublingual, buccal, intravenous,
intramuscular, subcutaneous, transdermal, and inhalation. Sublingual
administration drains directly into the superior vena cava via the sublingual vein,
completely bypassing the liver.
Question 3
A medication has a half-life of 8 hours. How long will it take to reach
approximately 94% steady-state concentration with consistent dosing?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32-40 hours (4-5 half-lives)
Answer: D
Rationale: Steady-state concentration is reached after approximately 4-5 half-lives.
With a half-life of 8 hours, 4-5 half-lives equals 32-40 hours. At this point,
approximately 94% of steady-state concentration is achieved. This principle is
essential for understanding when therapeutic drug levels will be attained after
initiating therapy.
Question 4
The NP prescribes a medication that is a substrate of CYP3A4. The patient is also
taking Clarithromycin (a strong CYP3A4 inhibitor). What is the expected effect on
the substrate medication?
, A. Decreased serum concentration and reduced therapeutic effect
B. Increased serum concentration and increased risk of toxicity
C. No change in serum concentration
D. Increased rate of metabolism
Answer: B
Rationale: CYP3A4 INHIBITORS (Clarithromycin, Erythromycin, Ketoconazole,
Itraconazole, Grapefruit juice, Ritonavir) DECREASE the metabolism of CYP3A4
substrates, leading to INCREASED serum concentrations and risk of TOXICITY.
Classic interactions: Clarithromycin + Simvastatin → increased rhabdomyolysis
risk. The NP should consider using an alternative antibiotic (e.g., Azithromycin,
which does not inhibit CYP3A4 significantly).
Question 5
A drug with a narrow therapeutic index (NTI) requires:
A. Less frequent monitoring
B. Close monitoring of serum drug levels to avoid toxicity or therapeutic failure
C. Higher than standard dosing
D. No special considerations
Answer: B
Rationale: Narrow Therapeutic Index (NTI) drugs have a small margin between the
minimum effective concentration and the minimum toxic concentration. Small
changes in dose, absorption, metabolism, or excretion can result in subtherapeutic
or toxic levels. Examples: Warfarin, Digoxin, Phenytoin, Theophylline, Lithium,
Aminoglycosides. NTI drugs require therapeutic drug monitoring.
Question 6
Which of the following best describes a competitive antagonist?
A. Binds to the same receptor site as the agonist and can be overcome by
increasing the agonist concentration
